Clinical investigations: investigators' responsibilities

AI Summary

This guidance document issued by the Medicines and Healthcare products Regulatory Agency (MHRA) outlines the essential requirements for manufacturers and clinical investigators planning to conduct clinical investigations for medical devices within the United Kingdom. Operating under the UK Medical Devices Regulations 2002, the document provides a comprehensive framework for the notification and approval process necessary to ensure participant safety and data integrity. While this specific guidance does not detail a single company's inspection or past violations, it establishes the standard against which all clinical trials are measured. Key requirements for applicants include the submission of detailed technical documentation, risk assessment profiles, and specific clinical investigation plans. Furthermore, the guidance specifies mandatory labeling standards for investigational devices, ensuring they are clearly identified as being for clinical use only. To proceed with a study, manufacturers must submit a formal notification to the MHRA and may only commence the investigation upon receiving a formal notification of 'no objection.' Required actions for compliance involve maintaining rigorous documentation, adhering to established ethical standards, and notifying the agency of any significant changes to the study protocol or adverse events. Failure to follow these established protocols can result in regulatory intervention or the suspension of clinical activities.